



THE CANCER DRUG DEVELOPMENT FORUM

FACILITATE. INNOVATE. DEBATE. COMMUNICATE.

Facilitating Debate, Fostering Innovation,
Accelerating Access to the Best Treatments
for All Cancer Patients

 info@cddf.org

 www.cddf.org

◎ WHAT IS THE CDDF

The Cancer Drug Development Forum (CDDF) is a **non-profit organisation** registered in **Belgium** that provides a **neutral platform** to stimulate **interaction between stakeholders** involved in **cancer drug development**.

◎ OUR MISSION

The CDDF's mission is to **provide a trusted space for all stakeholders** in cancer drug development to **facilitate dialogue, debate, and communication, fostering innovation** to **accelerate access to new (or the best) treatments** for all patients.

◎ HOW WE ADVANCE OUR MISSION

- ▶ The CDDF provides a **non-competitive, non-commercial platform** for **multi-stakeholder discussions** and **collaboration**.
- ▶ The CDDF **brings together all actors** in the oncology community such as **academia, the healthcare industry, regulatory authorities, health technology assessment (HTA) bodies, policymakers, and patient advocacy groups**.
- ▶ The CDDF **stimulates advancement and innovation** in the field through **scientific debate** and **open discussion**.

INITIATIVES

Since 2001, the Cancer Drug Development Forum (CDDF) has served as a **trusted space for all stakeholders** in cancer drug development to **facilitate dialogue, debate and communication**, fostering innovation to **accelerate access to new treatments for patients**.

The CDDF champions progress by hosting **dynamic conferences, workshops, conferences, webinars, and projects** that bring together stakeholders involved in oncology. In a **neutral, non-competitive environment**, we foster **productive dialogue and open, respectful interactions** in collaboration with the European Medicines Agency (EMA), the US Food and Drug Administration (FDA), and regulators from Europe and worldwide, alongside with academic researchers, pharmaceutical companies, HTA bodies, and patient advocates. Together, we **accelerate breakthroughs** and **access to effective treatments for all patients**.





FACILITATE. DEBATE. ACTIVATE. INNOVATE.

As a key part of the effort, the CDDF holds its **Annual Conference** that gathers key stakeholders and experts to address **challenges and opportunities in oncology drug development**. This interactive three-day meeting features plenary lectures with moderated discussions, offering multistakeholder perspectives and unique networking opportunities.

In addition to the Conference, the CDDF organizes **workshops, webinars and EU-level projects** to facilitate multi-stakeholder collaboration on **topical issues in the field of oncology**. The **responsive nature** of the CDDF platform enables the oncology community to initiate **timely conversations to reflect current and pressing needs**. We continue pioneering progress through upcoming programs, which explore the impact of digital AI approaches in discovery research and global and EU regulatory landscapes.

Through the **publication of white papers**, the CDDF goes the extra mile by **translating its meeting outcomes into actionable insights**, driving incremental, significant shifts in oncology.

We believe that **continued dialogue and active collaboration** are key to improving cancer treatments and accelerating patient access. We welcome all our stakeholders to join us in advancing this mission and making their voices heard.



**CDDF MEETINGS BRING
TOGETHER REGULATORS,
HTAs, THE HEALTHCARE
INDUSTRY, ACADEMICS, AND
PATIENT ADVOCATES TO
COLLABORATE**

**INCLUSIVE &
COLLABORATIVE NETWORK
OF MULTI-STAKEHOLDERS
INVOLVED IN ONCOLOGY
DRUG DEVELOPMENT**

CDDF LEADERSHIP

The CDDF is governed by a rotating board of directors, elected for three-year terms, dedicated to accelerating and optimizing cancer drug development and patient access. The board comprises distinguished individuals, including a patient advocate, pre-clinical and clinical investigators, medical oncologists, a pediatrician, and regulatory scientists, representing diverse perspectives within the drug development process.

These committed members bring vast experience from clinical, patient advocacy, industry and regulatory settings, ensuring the CDDF effectively functions as a neutral, non-competitive platform for all stakeholders involved in cancer drug development.

© CDDF BOARD OF DIRECTORS



**Mark
Lawler**

Chairperson



**Ruth
Plummer**

Managing
Director



**Stefan
Symeonides**

Vice-Chairperson



**Axel
Glasmacher**

Treasurer



**Jaap
Verweij**



**Rosa
Giuliani**



**Christian
Schneider**



**Fergus
Sweeney**



**Agnès
Saint-Raymond**



**Jana
Pelouchova**

CDDF staff members oversee the day to day running of the organisation. The head office is located in Brussels, Belgium.



Thierry Coppens
Director of Operations



Giorgia Campagnano
Event Manager



Shannon Adeux
Event Coordinator



Hyunmin Park
Community & Communication Coordinator



CDDF ACTIVITIES 2026

MULTI-STAKEHOLDER DISCUSSIONS

Cancer Drug Development Forum (CDDF)

ANNUAL CONFERENCE 2026

Cancer Clinical Research in a Changing Global Environment

9-11 February 2026
Ghent, BE



- [Executive summary](#)
- [Recordings/slides*](#)

CDDF Cancer Drug Development Forum

AAADV Accelerating Anticancer Agent Development and Validation

MULTI-STAKEHOLDER WORKSHOP

Challenges in the Landscape of a Global Development Strategy, including patient access

30 - 31 March 2026
Brussels, BE (hybrid)



- [Executive summary](#)
- [Recordings/slides](#)
- White paper (available soon)

CDDF Cancer Drug Development Forum

EORTC European Organisation for Research and Treatment of Cancer
The future of cancer therapy

CDDF & EORTC JOINT WORKSHOP

Health Technology Assessment in Cancer Drug Development

5 - 6 October 2026
Brussels, BE (hybrid)



- [Workshop programme](#)
- [Registration](#)



**Recent meeting recordings, slides and publications are accessible exclusively to the CDDF Industry Members via the CDDF Intranet platform. Sign up for the member access here: <https://cddf.org/member-access/>*

CDDF ACTIVITIES 2026

CDDF LIVE WEBINARS



LIVE WEBINAR

CDDF Live Webinar series – AI and Big Data AI in Drug Development: Use of AI in clinical trials

Dr. James Gulley (NIH)

12 May 2026
16:00-17:00 CET, Online



LIVE WEBINAR

CDDF Live Webinar series – AI and Big Data AI in Drug Development: transparency and risk assessment

Dr. Weida Tong (FDA)

16 June 2026
16:00-17:00 CET, Online



- [Key takeaways](#)
- [Recording/slides](#)
- [Webinar outline](#)
- [Registration](#)

Webinars in the Planning Stage

- CDDF Diversity Initiative paper
- Compassionate use / Expanded access programme in Europe
- Learning from “facilitating and accelerating strategic clinical trials in the EU” **pilot FAST EU**

Visit [the CDDF website](#) and follow us on [LinkedIn](#) to stay informed about upcoming webinars



MEETING OUTCOMES 2025

MULTI-STAKEHOLDER DISCUSSIONS

Cancer Drug Development Forum (CDDF)

ANNUAL CONFERENCE 2025

Challenges, Advances, and Open Questions in Global Cancer Drug Development and Clinical Trials

3-5 February 2025
Noordwijk aan Zee, NL



- [Executive summary](#)
- [Recordings/slides](#)
- [White paper: Challenges and Potential Solutions to Advance Global Cancer Drug Development](#) (Therapeutic Innovation & Regulatory Science, March 2026)

CDDF
Cancer Drug Development Forum

MULTI-STAKEHOLDER WORKSHOP

New Modalities in Cancer Drug Development

31 March - 1 April 2025
Brussels, BE (hybrid)



- [Executive summary](#)
- [Recordings/slides*](#)
- White paper (available soon)

CDDF
Cancer Drug Development Forum

MULTI-STAKEHOLDER WORKSHOP

Enabling smarter clinical trials to optimise patient care

DEPLOYING DATA TO DESIGN AND DELIVER BETTER TRIALS

17 - 18 November 2025
Brussels, BE (hybrid)



- [Executive summary](#)
- [Recordings/slides*](#)
- White paper (available soon)



**Recent meeting recordings, slides and publications are accessible exclusively to the CDDF Industry Members via the CDDF Intranet platform. Sign up for the member access here: <https://cddf.org/member-access/>*

MEETING OUTCOMES 2025

LIVE WEBINARS



LIVE WEBINAR

EU HTA Regulation

Michael Berntgen (EMA)
Niklas Hedberg (TLV)
Vanessa Schaub (Roche)

12 March 2025
17:00-18:00 CET, Online



- [Key takeaways](#)
- [Recordings/slides](#)



LIVE WEBINAR

Using AI in assessing cancer treatment response on imaging: Project Data Sphere

Sean Khozin (Project Data Sphere, US)
Christopher Medberry (J&J, US)

23 April 2025
17:00-18:00 CEST, Online



- [Key takeaways](#)
- [Recordings/slides](#)



LIVE WEBINAR SERIES:
Bayesian Framework

Bayesian Approaches in Oncology Drug Development: Introduction and Motivations

Purvi Prajapati (Eli Lilly)
Natalia Muhlemann (Cytel)

14 May 2025
17:00-18:00 CEST, Online



- [Key takeaways](#)
- [Recordings/slides](#)



LIVE WEBINAR SERIES
AI and Big Data AI in drug development

Transformation of future clinical trials using AI-enhanced imaging biomarkers

Johannes Haubold (University of Essen)
Sasa Grbic (Siemens Healthineers)

18 September 2025
17:00-18:00 CEST, Online



- [Key takeaways](#)
- [Recordings/slides](#)



LIVE WEBINAR

Long term outcomes of in utero exposure to cytotoxic therapy: is involving pregnant patients an absolute no-go in cancer drug development?

Frédéric Amant (UZ Leuven)

4 December 2025
16:00-17:00 CET, Online



- [Key takeaways](#)
- [Recordings/slides](#)



LIVE WEBINAR SERIES: ACT EU

ACT EU: Collaborating with stakeholders to define priorities for clinical trials and working collectively to address them

Marianne Lunzer (Austrian Medicines Agency)
Laura Pioppo (EMA)

15 December 2025
16:00-17:00 CET, Online



- [Key takeaways](#)
- [Recordings/slides](#)



COLLABORATION AND OPEN DIALOGUE AMONG ALL STAKEHOLDERS ARE KEY TO IMPROVING OUTCOMES FOR CANCER PATIENTS

 info@cddf.org

 www.cddf.org

 [@cddf_eu](https://twitter.com/cddf_eu)

 [The Cancer Drug Development Forum \(CDDF\)](https://www.linkedin.com/company/cddf/)

 Cancer Drug Development Forum asbl
Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium

 The CDDF is a non-profit association in the register of legal entities at the French
Speaking Enterprise Court in Brussels. Enterprise number: 738.523.752